Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285697265> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4285697265 endingPage "437" @default.
- W4285697265 startingPage "432" @default.
- W4285697265 abstract "To evaluate the immunomodulatory effect of T-AYU-HM Premium in experimental animal models. Female Wistar rats were divided into four groups in each model and acclimatized under standard conditions. The control group received vehicle (0.5% CMC), the standard group received Levamisole (50 mg/kg), Test-1 group received T-AYU-HM Premium (600 mg/kg), and Test-2 group received T-AYU-HM Premium (1200 mg/kg). The effect of T-AYU-HM Premium as an immunomodulator was studied by evaluating the neutrophil adhesion model, carbon clearance model, cyclophosphamide-induced neutropenia model, and haemagglutinating antibody titer model. The neutrophil adhesion in standard, Test-1, and Test-2 are 55.39%, 23.32%, and 38.06%, respectively. The %reduction of TLC and DLC in standard and both test groups were significant compared to the control group after nylon fiber treatment. The phagocytic index of standard, test-1 and test-2 was found to be 0.01735, 0.01416, and 0.00923, respectively, this indicates that the test drug affects the reticuloendothelial system. A significant decrease in cyclophosphamide-induced neutropenia implies that the cyclophosphamides’ influence on the hemopoietic system is lessened. The percentage reduction in TLC of standard and both test drug groups are 11.12%, 20.66%, and 13.43%, respectively. The %reduction in DLC of standard and both test drug groups were significant compared to a control group. Haemagglutinating antibody (HA) titer test determines the effect of the drug on humoral immunity. Primary HA titer values of standard, test-1 and test-2 were 5.33, 2.66, and 4.50, respectively. Secondary HA titer values of standard, test-1, and test-2 were 13, 7.16, and 11.16, respectively. HA titer value significantly increases in standard and test groups compared to control in both primary and secondary evaluation. In the current study, results show that the T-AYU-HM Premium tablets exhibit Immunomodulatory activity" @default.
- W4285697265 created "2022-07-18" @default.
- W4285697265 creator A5008759429 @default.
- W4285697265 creator A5039595463 @default.
- W4285697265 creator A5068407938 @default.
- W4285697265 creator A5070312333 @default.
- W4285697265 creator A5080657820 @default.
- W4285697265 creator A5085269680 @default.
- W4285697265 creator A5086300495 @default.
- W4285697265 date "2020-03-30" @default.
- W4285697265 modified "2023-10-16" @default.
- W4285697265 title "Immunomodulatory study, Levamisole, Neutrophil adhesion,T-AYU-HM Premium." @default.
- W4285697265 doi "https://doi.org/10.25004/ijpsdr.2021.130409" @default.
- W4285697265 hasPublicationYear "2020" @default.
- W4285697265 type Work @default.
- W4285697265 citedByCount "0" @default.
- W4285697265 crossrefType "journal-article" @default.
- W4285697265 hasAuthorship W4285697265A5008759429 @default.
- W4285697265 hasAuthorship W4285697265A5039595463 @default.
- W4285697265 hasAuthorship W4285697265A5068407938 @default.
- W4285697265 hasAuthorship W4285697265A5070312333 @default.
- W4285697265 hasAuthorship W4285697265A5080657820 @default.
- W4285697265 hasAuthorship W4285697265A5085269680 @default.
- W4285697265 hasAuthorship W4285697265A5086300495 @default.
- W4285697265 hasBestOaLocation W42856972651 @default.
- W4285697265 hasConcept C126322002 @default.
- W4285697265 hasConcept C159654299 @default.
- W4285697265 hasConcept C185592680 @default.
- W4285697265 hasConcept C203014093 @default.
- W4285697265 hasConcept C2776694085 @default.
- W4285697265 hasConcept C2776755627 @default.
- W4285697265 hasConcept C2777063308 @default.
- W4285697265 hasConcept C2781325985 @default.
- W4285697265 hasConcept C29730261 @default.
- W4285697265 hasConcept C32611913 @default.
- W4285697265 hasConcept C71924100 @default.
- W4285697265 hasConceptScore W4285697265C126322002 @default.
- W4285697265 hasConceptScore W4285697265C159654299 @default.
- W4285697265 hasConceptScore W4285697265C185592680 @default.
- W4285697265 hasConceptScore W4285697265C203014093 @default.
- W4285697265 hasConceptScore W4285697265C2776694085 @default.
- W4285697265 hasConceptScore W4285697265C2776755627 @default.
- W4285697265 hasConceptScore W4285697265C2777063308 @default.
- W4285697265 hasConceptScore W4285697265C2781325985 @default.
- W4285697265 hasConceptScore W4285697265C29730261 @default.
- W4285697265 hasConceptScore W4285697265C32611913 @default.
- W4285697265 hasConceptScore W4285697265C71924100 @default.
- W4285697265 hasIssue "04" @default.
- W4285697265 hasLocation W42856972651 @default.
- W4285697265 hasOpenAccess W4285697265 @default.
- W4285697265 hasPrimaryLocation W42856972651 @default.
- W4285697265 hasRelatedWork W1482869986 @default.
- W4285697265 hasRelatedWork W2016347068 @default.
- W4285697265 hasRelatedWork W2033331638 @default.
- W4285697265 hasRelatedWork W2047262583 @default.
- W4285697265 hasRelatedWork W2080750171 @default.
- W4285697265 hasRelatedWork W2103974498 @default.
- W4285697265 hasRelatedWork W2410369054 @default.
- W4285697265 hasRelatedWork W2436662853 @default.
- W4285697265 hasRelatedWork W2748952813 @default.
- W4285697265 hasRelatedWork W2899084033 @default.
- W4285697265 hasVolume "13" @default.
- W4285697265 isParatext "false" @default.
- W4285697265 isRetracted "false" @default.
- W4285697265 workType "article" @default.